Clinical and genetic profile of catecholaminergic polymorphic ventricular tachycardia in Hong Kong Chinese children by Yung, TC et al.
Title Clinical and genetic profile of catecholaminergic polymorphicventricular tachycardia in Hong Kong Chinese children
Author(s) Yu, TC; Yung, TC; Lun, KS; Chung, BHY; Liu, APY




Hong Kong Medical Journal. Copyright © Hong Kong Academy
of Medicine Press.; This work is licensed under a Creative
Commons Attribution-NonCommercial-NoDerivatives 4.0
International License.
314 Hong Kong Med J  ⎥  Volume 22 Number 4  ⎥  August 2016  ⎥  www.hkmj.org
A B S T R A C T 
Objective: To report our experience in the 
management of catecholaminergic polymorphic 
ventricular tachycardia in Hong Kong Chinese 
children.
Methods: This case series study was conducted in a 
tertiary paediatric cardiology centre in Hong Kong. 
All paediatric patients diagnosed at our centre 
with catecholaminergic polymorphic ventricular 
tachycardia from January 2008 to October 2014 were 
included. 
Results: Ten patients (five females and five males) 
were identified. The mean age at presentation and at 
diagnosis were 11.0 (standard deviation, 2.9) years 
and 12.5 (2.8) years, respectively. The mean delay 
time from first presentation to diagnosis was 1.5 
(standard deviation, 1.3) years. They presented with 
recurrent syncope and six patients had a history of 
aborted cardiac arrest. Four patients were initially 
misdiagnosed to have epilepsy. Catecholaminergic 
polymorphic ventricular tachycardia was diagnosed 
by electrocardiogram at cardiac arrest (n=2), or 
provocation test, either by catecholamine infusion 
test (n=6) or exercise test (n=2). Mutations of the 
RyR2 gene were confirmed in six patients. Nine 
patients were commenced on beta-blockers after 
diagnosis. Despite medications, three patients 
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Introduction
Catecholaminergic polymorphic ventricular 
tachycardia (CPVT) is an inherited arrhythmia 
syndrome. Mutation of the ryanodine receptor 
2 (RyR2) gene and infrequently the calsequestrin 
(CASQ2) gene is identified in approximately 60% 
to 70% of patients.1,2 Patients with CPVT usually 
present with syncope and sudden cardiac death. 
The symptoms are due to bidirectional polymorphic 
ventricular tachycardia (VT) induced by adrenergic 
stress.1 Onset of arrhythmia syndrome is usually in 
New knowledge added by this study
• This is the first study of catecholaminergic polymorphic ventricular tachycardia (CPVT) in Hong Kong 
describing local experience in the management of this rare arrhythmic syndrome.
• The genetic background (RyR2 mutation) of our Chinese children is similar to those in overseas studies.
Implications for clinical practice or policy
• CPVT should be considered in young patients who present with exercise-related syncope. 
• Maintaining a high index of suspicion and correct diagnosis of CPVT may be life-saving.
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childhood. Many affected children are considered to 
have vasovagal syncope or epilepsy before a correct 
diagnosis is made.1-4 If left untreated, the mortality of 
CPVT is up to 31% by the age of 30 years.1,3,5
 In this study, we reviewed the clinical 
characteristics, genetic profile, and outcome of 
CPVT in Hong Kong Chinese children. 
Methods 
Our study included children diagnosed with CPVT 
from January 2008 to October 2014 at Queen Mary 
ORIGINAL ARTICLE
developed aborted or resuscitated cardiac arrest 
(n=2) and syncope (n=1). Left cardiac sympathetic 
denervation was performed in five patients and an 
implantable cardioverter defibrillator was implanted 
in another. There was no mortality during follow-up. 
Conclusions: Catecholaminergic polymorphic 
ventricular tachycardia should be considered in 
children who present with recurrent syncope during 
exercise or emotional stress. Despite beta-blocker 
treatment, recurrent ventricular arrhythmias occur 
and may result in cardiac arrest. 
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Hospital, a university-affiliated teaching hospital in 
Hong Kong. The hospital records were retrospectively 
reviewed. Demographic data, clinical presentation, 
diagnostic methods, and genetic tests were reviewed. 
In all patients, the heart rate–corrected QT interval 
of the resting electrocardiogram was normal and the 
presence of structural heart disease was excluded 
by echocardiography (n=10) and/or magnetic 
resonance imaging (n=5). We also summarised the 
treatment modalities, response to treatment, and 
clinical outcome up to October 2014. 
Genetic analysis
Blood samples of seven patients were sent to 
the Molecular Genetics Laboratory of Victorian 
Clinical Genetic Services, Australia where testing 
for mutations of the RyR2 gene was performed. The 
assay involved sequencing of 17 hotspot exons (exons 
1, 8, 14, 15, 44, 46, 47, 49, 88, 93, 95, 97, 101, 102, 
103, 104, 105), their splice junctions and 20 bps into 
the introns. Since 2014, the Laboratory has made 
use of a cardiac next-generation sequencing panel 
to analyse the 28 arrhythmia genes: AKAP9, ANK2, 
CACNA1C, CACNA2D1, CACNB2, CASQ2, CAV3, 
GJA5, GPD1L, HCN4, KCNA5, KCND3, KCNE1, 
KCNE1L, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, 
KCNJ8, KCNQ1, NPPA, RYR2, SCN1B, SCN3B, 
SCN4B, SCN5A, and SNTA1. In two patients, the 
samples were tested by the local Laboratory Genetic 
Service (Department of Pathology, Princess Margaret 
Hospital, Hong Kong), where direct sequencing of 
selected hotspot exons and the flanking introns (10 
bps) was performed. Cascade testing was offered for 
first-degree relatives of genotype-positive subjects.
Results
Characteristics of the study subjects
During the study period, 10 patients were diagnosed 
to have CPVT. Their demographic data and clinical 
TABLE 1.  Demographic data, clinical presentation, diagnostic method, and the threshold heart rate of polymorphic ventricular ectopic and ventricular 
tachycardia of the 10 patients
Patient 
No.

























1 Male 6.2 6.9 0.7 6.7 Syncope Isoprenaline infusion 426 120 140
2 Female 11.0 14.1 3.1 5.5 Syncope Adrenaline infusion 394 110 142
3 Female 9.7 13.0 3.3 6.4 Syncope Treadmill 416 150 150
4 Female 14.2 14.3 0.1 4.7 Aborted cardiac arrest Arrest ECG 422 90 126
5* Male 11.6 14.9 3.4 2.9 Syncope Treadmill 406 125 NA
6 Female 7.2 9.2 2.0 2.7 Aborted cardiac arrest Adrenaline infusion 396 110 166
7 Female 13.7 15.1 1.4 2.7 Syncope Adrenaline infusion 444 126 170
8 Male 13.2 13.2 0 2.4 Aborted cardiac arrest Adrenaline infusion 380 117 138
9* Male 14.0 14.4 0.3 2.0 Aborted cardiac arrest Arrest ECG 423 NA NA
10 Male 9.3 10.0 0.7 0.7 Syncope Adrenaline infusion 404 120 130
Abbreviations: ECG = electrocardiogram; NA = not available; QTc = heart rate–corrected QT; VE = ventricular ectopic; VT = ventricular tachycardia
* Brothers of the same family
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features are summarised in Table 1. The group 
comprised five female and five male patients; two 
of whom were brothers. The mean (± standard 
deviation) age at first presentation was 11.0 ± 2.9 
(range, 6.2-14.2) years. The mean age at diagnosis 
was 12.5 ± 2.8 (range, 6.9-15.1) years. The mean 
delay time from first presentation to diagnosis was 
1.5 ± 1.3 years. 
 Six patients presented initially with syncope 
while the other four presented with aborted cardiac 
arrest. At the end of the study, a total of six patients 
had aborted cardiac arrest. The triggering event 
for syncope or cardiac arrest was either exercise or 
emotion. Nonetheless, no such event was evident in 
three patients. 
 Four patients were initially misdiagnosed 
with epilepsy, one of whom was treated with an 
anticonvulsant prior to the diagnosis of CPVT. 
 Of the four patients who presented with 
aborted cardiac arrest, three required repeated 
cardioversion because of recurrent VT immediately 
following successful termination of ventricular 
arrhythmias. The case of patient 4 has been reported 
previously.6
Diagnosis of catecholaminergic polymorphic 
ventricular tachycardia and genetic analysis
Diagnosis of CPVT in two patients was based on 
the presence of bidirectional polymorphic VT in the 
cardiac arrest electrocardiogram. In the remaining 
patients, diagnosis was made when polymorphic or 
bidirectional VT was induced during provocation 
tests by exercise (n=2) or catecholamine infusion 
(n=6). Heart rate at the induction of ventricular 
premature beats ranged from 90 to 150 beats/min. 
Polymorphic VTs were induced when heart rate was 
increased to 126 to 170 beats/min (Fig).
 Of the nine patients with genetic study, six 
were confirmed to have mutations of the RyR2 gene 
as shown in Table 2. One patient (patient 9) did not 
undergo genetic study because his brother (patient 
5) was confirmed to have no mutation of RyR2. Only 
two (brothers of the same family) of 10 patients had 
a family history of cardiac arrhythmic events. There 
was no RyR2 mutation identified in the first-degree 
relatives of any patient with a RyR2 mutation. 
Treatment and response
Medical treatment
The treatment modalities and response are 
summarised in Table 3. All patients were started 
on a beta-blocker as first-line medication. One 
patient initially refused medical treatment. She then 
had recurrent syncope and subsequently agreed to 
treatment with nadolol. 
 Metoprolol was prescribed to three patients 
as initial medical treatment, although all switched 
to nadolol with or without flecainide due to 
unsatisfactory control (aborted cardiac arrest in one 
and exercise-induced polymorphic VT in another) 
or intolerable side-effects (tiredness and significant 
bradycardia at 38 beats/min). 
 Of the six patients prescribed nadolol as the 
first medication, five had no more syncope and 
no VT on treadmill exercise testing. Nadolol was 
changed to flecainide in one patient (patient 7) due 
to significant resting bradycardia of 35 beats/min. 
Nadolol was later resumed at a lower dose. 
 Atenolol was started in one girl as initial 
medical treatment but failed to prevent recurrent 
syncope. After changing to nadolol, she remained 
symptomatic and subsequently underwent left 
cardiac sympathetic denervation (LCSD). 
Additional treatments
Left cardiac sympathetic denervation was performed 
via a video-assisted thoracoscopic approach in five 
FIG.  Patient 1: (a) polymorphic ventricular ectopics, with bidirectional QRS 
complexes induced by exercise test; and (b) polymorphic ventricular tachycardia, 
with bidirectional QRS complexes recorded by Holter monitoring
(a)
(b)
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patients. The lower half of the stellate ganglion and 
the sympathetic trunk of T2 to T4 were resected. 
After LCSD, one patient (patient 1) still had recurrent 
syncope. The other four patients had no more 
syncope. Dual-chamber implantable cardioverter 
defibrillator (ICD) implantation was performed 
in one patient (patient 7) who experienced an 
aborted cardiac arrest despite flecainide. She had 
no complications related to the ICD implantation. 
After implantation, she had one episode of syncope 
TABLE 2.  RyR2 mutations identified in our cohort
Patient 
No.
Detection method Nucleotide 
change
Mutation Novel
1 Sequencing of selected hotspot (exon 105)* 14848G>A E4950K No
2 NGS – arrhythmia panel 12475C>A Q4159K Yes
3 Sequencing of 17 hotspots Negative Negative Not applicable
4 Sequencing of 17 hotspots 7420A>G R2474G Yes
5 Sequencing of 17 hotspots Negative Negative Not applicable
6 Sequencing of selected hotspots (exons 3, 8, 14, 46, 47, 49, 88, 89, 90, 93, 97, 100, 
101, 103)*
11836G>A G3946S No
7 Sequencing of 17 hotspots Negative Negative Not applicable
8 Sequencing of 17 hotspots 14861C>G A4954G Yes
9 Not tested (as sibling tested negative) - - -
10 NGS – arrhythmia panel 12475C>A Q4159K Yes
Abbreviation: NGS = next-generation sequencing
* Test performed in local Laboratory Genetic Service
TABLE 3.  The medical and surgical treatment, most-severe arrhythmic events during follow-up, and the latest Holter or Treadmill results with current 













rate at last 
follow-up 
(beats/min)
Latest Holter / Treadmill results with 
current treatment
1 Positive Metoprolol 25 mg BD Nadolol 60 mg daily + 
flecainide 50 mg BD + LCSD
Aborted 
cardiac arrest
39 Holter: still polymorphic VT at 182/min
Treadmill: no exercise-induced 
tachyarrhythmia 
2 Positive Metoprolol 50 mg BD Flecainide 100 mg/150 mg BD 
+ LCSD
Nil 37 Holter: no VE or VT
Treadmill: polymorphic VE (triplets), less 
sustained
3 Negative Refused Nadolol 40 mg daily Syncope 53 Treadmill: much less polymorphic VEs, 
no VT
4 Positive Atenolol 50 mg daily Nadolol 40 mg daily + LCSD Syncope 46 Treadmill (after LCSD): less frequent 
exercise-induced VEs; no VT
5 Negative Nadolol 60 mg daily Nadolol 60 mg daily Nil 52 Holter: no VE or VT
Treadmill: frequent monomorphic VE 
but no VT induced
6 Positive Nadolol 60 mg daily Nadolol 80 mg daily + LCSD Nil 53 Holter and Treadmill with current 
treatment not performed yet at the end 
of study
7 Negative Nadolol 10 mg daily Nadolol 20 mg daily + 
flecainide 150 mg BD + ICD
Aborted 
cardiac arrest
59 Holter: no VE
Treadmill: no exercise-induced VE 
8 Positive Metoprolol 50/75 mg 
BD
Nadolol 100 mg daily + 
flecainide 100 mg BD + LSCD
Nil 47 Treadmill: no VE or VT
9 Refused Nadolol 80 mg daily Nadolol 80 mg daily Nil 62 Treadmill: no exercise-induced VE or VT 
10 Positive Nadolol 20 mg daily Nadolol 80 mg daily Nil 60 Treadmill: short runs of polymorphic VT 
(5 beats)
Abbreviations: BD = twice daily; ICD = implantable cardioverter defibrillator ; LCSD = left cardiac sympathetic denervation; VE = ventricular ectopic; VT = 
ventricular tachycardia
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while she was swimming slowly in the pool with her 
mother. She was taken out of the water and was able 
to stand unaided soon after. The ICD interrogation 
noted an episode of VT/ventricular fibrillation that 
was successfully aborted by electric shocks from the 
ICD. She had no inappropriate shocks from the ICD 
during the follow-up period of 30 months. 
Outcomes
The median duration of follow-up was 3.7 ± 2.0 
(range, 0.7-6.7) years. Six (60%) patients became 
asymptomatic after drug treatment. Two patients 
had recurrent syncope; one of whom was without 
drug treatment. Two patients experienced aborted 
cardiac arrest, one received ICD implantation and 
another one refused. There was no mortality during 
the study period. 
Discussion 
Catecholaminergic polymorphic ventricular 
tachycardia is uncommon in Hong Kong Chinese 
children. Our centre treated most of the serious local 
paediatric cardiac arrhythmia cases. Over a period 
of 7 years we identified only 10 patients. Our case 
series is, to date, the largest in Chinese children.
 Many of our patients (6 out of 10) had 
experienced aborted cardiac arrest as the near-
fatal arrhythmic event during the study. The 
diagnosis of CPVT can be challenging and requires 
documentation of typical bidirectional polymorphic 
VT at presentation, or induction of polymorphic VT 
by exercise test or catecholamine infusion test.1-3,7,8 
Studies show that diagnosis of CPVT can be made 
in 69% and 75% of patients by exercise test and 
catecholamine infusion test, respectively.9,10 
 Misdiagnosis and delay in diagnosis of CPVT is 
common. Our patients had a mean delay of 1.5 years 
from first presentation to diagnosis. Four of our 
patients were initially misdiagnosed with epilepsy, 
one of whom was prescribed anticonvulsant therapy. 
Of the 10 patients, four were not diagnosed until 
they presented with aborted cardiac arrest. 
 Genetic mutations are identified in 60% to 
70% of patients with CPVT, and more than 90% 
of the mutations affect the RyR2 gene.1,3 Mutation 
of the CASQ2 gene is rare (<2%). Very recently, 
mutation of triadin, a transmembrane sarcoplasmic 
reticulum protein, was found to be the cause of 
CPVT in two families.11 In these mutations, the 
defective proteins cause excessive calcium release 
from the sarcoplasmic reticulum to the cytoplasm 
leading to polymorphic VT.1,5 Similar to overseas 
studies, mutation of the RyR2 gene was evident in 
the majority (60%) of our patients. 
 Patients with CPVT must be restricted from 
exercise to avoid the adrenergic trigger. A beta-
blocker serves as first-line medical therapy.1,2,4,10 
Nonetheless, CPVT is a very malignant arrhythmic 
disease and many patients remain symptomatic 
despite such therapy.1,3,4,10 In a systematic analysis of 
354 CPVT patients treated with beta-blockers, the 
estimated 8-year arrhythmic event rate was 37.2%.12 
Our study also showed that a high proportion of 
patients still developed arrhythmic events despite 
beta-blocker treatment (syncope in one and aborted 
cardiac arrest in two out of 10 patients). 
 In the early period of study, we prescribed 
metoprolol in three patients, although all experienced 
treatment failure due to recurrent symptoms or 
intolerance. In the later period, nadolol was the 
initial medication and five out of six patients became 
asymptomatic. 
 Flecainide, a class 1c anti-arrhythmic drug with 
dual action of direct ryanodine receptor blockage 
and blockage of sodium channels,1,12 may be effective 
in CPVT patients. Flecainide has been evaluated in a 
multicentre study of 33 CPVT patients. In 22 (76%) 
out of 29 patients, flecainide suppressed exercise-
induced ventricular arrhythmia either partially (n=8) 
or completely (n=14).1,12,13 In our study, flecainide was 
used in four patients who had failed treatment with 
a beta-blocker. Three patients still had arrhythmic 
events, however.
 Studies showed that LCSD, which prevents 
noradrenaline release in the heart, is highly effective 
in severely affected CPVT patients.14,15 It can be 
performed with a minimally invasive approach by 
video-assisted thoracic surgery. In our study, five 
patients underwent LCSD. All recovered well and no 
complications were noted at follow-up. Four had no 
more syncope. Large studies are needed to further 
evaluate its efficacy in CPVT patients.
 An ICD has been recommended in patients 
who fail optimised medical therapy.1,12,14,16 Some 
recent studies have suggested that ICD may be 
harmful to CPVT patients, however, because both 
appropriate and inappropriate ICD shocks can 
potentially induce VT storms and cardiac arrest.16,17 
Therefore, ICD implantation should be restricted 
to patients with symptoms refractory to optimised 
medical treatment and LCSD.18 
Conclusions
Catecholaminergic polymorphic ventricular 
tachycardia is an uncommon but malignant cardiac 
arrhythmia that presents as syncope, seizure, or 
sudden cardiac death in childhood. In our study, 
60% of patients experienced aborted cardiac arrest. 
One should suspect the diagnosis when syncope 
occurs during exercise or emotional stress. Similar 
to overseas studies, RyR2 mutation is the most 
common genetic mutation and affected 60% of our 
patients. Despite optimised medical therapy, 60% of 
patients still required LCSD or ICD implantation. 
#  Catecholaminergic polymorphic ventricular tachycardia  # 
319Hong Kong Med J  ⎥  Volume 22 Number 4  ⎥  August 2016  ⎥  www.hkmj.org
Acknowledgements
The expenses of genetic analysis were sponsored by 
the Children’s Heart Foundation of Hong Kong. 
Declaration
All authors have no relevant conflicts of interest to 
disclose.
References
1. Ylänen K, Poutanen T, Hiippala A, Swan H, Korppi M. 
Catecholaminergic polymorphic ventricular tachycardia. 
Eur J Pediatr 2010;169:535-42.
2. Priori SG, Napolitano C, Memmi M, et al. Clinical 
and molecular characterization of patients with 
catecholaminergic polymorphic ventricular tachycardia. 
Circulation 2002;106:69-74.
3. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel 
P. Catecholaminergic polymorphic ventricular tachycardia 
in children. A 7-year follow-up of 21 patients. Circulation 
1995;91:1512-9.
4. Çeliker A, Erdoğan I, Karagöz T, Özer S. Clinical experiences 
of patients with catecholaminergic polymorphic ventricular 
tachycardia. Cardiol Young 2009;19:45-52.
5. Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder 
mapped to chromosome 1q42-q43 causes malignant 
polymorphic ventricular tachycardia in structurally normal 
hearts. J Am Coll Cardiol 1999;34:2035-42. 
6. Kung SW, Yung TC, Chiu WK. Successful resuscitation of 
out-of-hospital ventricular fibrillation cardiac arrest in an 
adolescent. Hong Kong J Emerg Med 2010;17:482-7. 
7. Lahat H, Eldar M, Levy-Nissenbaum E, et al. Autosomal 
recessive catecholamine- or exercise-induced polymorphic 
ventricular tachycardia: clinical features and assignment 
of the disease gene to chromosome 1p13-21. Circulation 
2001;103:2822-7.
8. Postma AV, Denjoy I, Kamblock J, et al. Catecholaminergic 
polymorphic ventricular tachycardia: RYR2 mutations, 
bradycardia, and follow up of the patients. J Med Genet 
2005;42:863-70.
9. Marjamaa A, Hiippala A, Arrhenius B, et al. Intravenous 
epinephrine infusion test in diagnosis of catecholaminergic 
polymorphic ventricular tachycardia. J Cardiovasc 
Electrophysiol 2012;23:194-9. 
10. Sumitomo N, Harada K, Nagashima M, et al. 
Catecholaminergic polymorphic ventricular tachycardia: 
electrocardiographic characteristics and optimal 
therapeutic strategies to prevent sudden death. Heart 
2003;89:66-70.
11. Roux-Buisson N, Cacheux M, Fourest-Lieuvin A, et 
al. Absence of triadin, a protein of the calcium release 
complex, is responsible for cardiac arrhythmia with sudden 
death in human. Hum Mol Genet 2012;21:2759-67. 
12. van der Werf C, Zwinderman AH, Wilde AA. Therapeutic 
approach for patients with catecholaminergic polymorphic 
ventricular tachycardia: state of the art and future 
developments. Europace 2012;14:175-83.
13. van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide 
therapy reduces exercise-induced ventricular arrhythmias 
in patients with catecholaminergic polymorphic ventricular 
tachycardia. J Am Coll Cardiol 2011;57:2244-54.
14. Wilde AA, Bhuiyan ZA, Crotti L, et al. Left cardiac 
sympathetic denervation for catecholaminergic 
polymorphic ventricular tachycardia. N Engl J Med 
2008;358:2024-9. 
15. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical 
management of catecholaminergic polymorphic 
ventricular tachycardia: the role of left cardiac sympathetic 
denervation. Circulation 2015;131:2185-93.
16. Miyake CY, Webster G, Czosek RJ, et al. Efficacy of 
implantable cardioverter defibrillators in young patients 
with catecholaminergic polymorphic ventricular 
tachycardia: success depends on substrate. Circ Arrhythm 
Electrophysiol 2013;6:579-87.
17. Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden 
cardiac death despite an implantable cardioverter-
defibrillator in a young female with catecholaminergic 
ventricular tachycardia. Heart Rhythm 2006;3:1486-9.
18. van der Werf C, Wilde AA. Catecholaminergic polymorphic 
ventricular tachycardia: from bench to bedside. Heart 
2013;99:497-504. 
